Reported results
- Research and development (R&D) expense was $6.6 million for the three months ended September 30, 2026, compared to $15.9 million for the three months ended September 30, 2025.
- General and administrative (G&A) expense was $4.5 million for the three months ended September 30, 2026, compared to $4.4 million for the three months ended September 30, 2025.
- Net loss was $10.7 million for the three months ended September 30, 2026, compared to $19.4 million for the three months ended September 30, 2025.
- Basic and diluted net loss per common share was $0.24 for the three months ended September 30, 2026, compared to $0.54 for the three months ended September 30, 2025.
- Cash, cash equivalents, and marketable securities were $20.0 million as of September 30, 2026.
Guidance
- Vistagen believes its cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027 but are not expected to be sufficient to extend the Company’s cash runway for more than a year from the date of the release.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
